600285.SHG Henan Lingrui Pharmaceutical Co Ltd
- Market cap
- CNY 13.4B
- P/E
- 16.1x
- P/B
- 3.87x
- ROE
- 27.7%
- Dividend yield
- 3.83%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600285.SHG undervalued?
Graham number600285.SHG trades 66.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Henan Lingrui Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Henan Lingrui Pharmaceutical Co Ltd yet.
Henan Lingrui Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Medical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, nutritio…
Full company profileHenan Lingrui Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Henan Lingrui Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.44B | 1.85B | 2.05B | 2.16B | 2.33B | 2.69B | 3.00B | 3.31B | 3.50B | 3.85B | 4.19B |
| Gross Profit | 964M | 1.35B | 1.56B | 1.66B | 1.78B | 1.99B | 2.16B | 2.42B | 2.65B | 3.08B | 3.31B |
| Operating Income | 404M | 267M | 294M | 341M | 367M | 435M | 517M | 656M | 810M | 838M | 1.06B |
| EBITDA | 215M | 297M | 362M | 396M | 385M | 448M | 463M | 665M | 795M | 982M | 1.12B |
| Net Income | 346M | 217M | 243M | 294M | 325M | 362M | 465M | 568M | 723M | 760M | 958M |
| EPS | 0.60 | 0.37 | 0.41 | 0.52 | 0.57 | 0.64 | 0.82 | 1.00 | 1.28 | 1.34 | 1.69 |
| Balance Sheet | |||||||||||
| Total Assets | 2.98B | 3.31B | 3.11B | 3.32B | 3.46B | 3.79B | 4.34B | 4.77B | 5.02B | 5.64B | 6.17B |
| Total Liabilities | 869M | 1.10B | 1.02B | 1.10B | 1.14B | 1.51B | 1.79B | 1.97B | 1.94B | 2.20B | 2.68B |
| Shareholders' Equity | 2.09B | 2.17B | 2.08B | 2.21B | 2.31B | 2.28B | 2.55B | 2.79B | 3.07B | 3.40B | 3.46B |
| Cash & Short-term Investments | 391M | 351M | 649M | 769M | 790M | 1.08B | 1.33B | 1.50B | 1.51B | 383M | 762M |
| Total Debt | 225M | 285M | 201M | 135M | 20.0M | 136M | 101M | 149M | 39.8M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 63.3M | 106M | 436M | 450M | 451M | 846M | 835M | 813M | 876M | 554M | - |
| Capital Expenditure | 218M | 258M | 52.1M | 59.0M | 71.8M | 76.9M | 27.0M | 21.2M | 115M | 56.8M | 54.7M |
| Free Cash Flow | -155M | -152M | 384M | 391M | 379M | 769M | 808M | 792M | 761M | 497M | 1.31B |
| Ratios | |||||||||||
| ROE | 16.6% | 10.0% | 11.7% | 13.3% | 14.1% | 15.9% | 18.2% | 20.4% | 23.5% | 22.3% | 27.7% |
| ROA | 11.6% | 6.6% | 7.8% | 8.9% | 9.4% | 9.5% | 10.7% | 11.9% | 14.4% | 13.5% | 15.5% |
| Net Profit Margin | 24.0% | 11.7% | 11.8% | 13.6% | 14.0% | 13.4% | 15.5% | 17.2% | 20.6% | 19.7% | 22.9% |
| Debt to Equity | 0.11x | 0.13x | 0.10x | 0.06x | 0.01x | 0.06x | 0.04x | 0.05x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Henan Lingrui Pharmaceutical Co Ltd dividends
- Dividend yield
- 3.83%
- Forward dividend
- 1.10 CNY
- Payout ratio
- 67.3%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 511M | 0.90 | 67.3% |
| 2024 | CNY 451M | 0.80 | 62.5% |
| 2023 | CNY 344M | 0.61 | 60.6% |
| 2022 | CNY 282M | 0.50 | 60.6% |
| 2021 | CNY 221M | 0.39 | 61.0% |
| 2020 | CNY 170M | 0.30 | 52.3% |
| 2019 | CNY 87.0M | 0.15 | 29.5% |
| 2018 | CNY 105M | 0.18 | 43.3% |
| 2017 | CNY 98.8M | 0.17 | 45.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on Jul 2, 2014.
Who owns Henan Lingrui Pharmaceutical Co Ltd
- Insiders 24.02%
- Institutions 11.45%
- Public & others 64.53%
- Shares outstanding 567M
- Free float 436M
Henan Lingrui Pharmaceutical Co Ltd company profile
- Company name
- Henan Lingrui Pharmaceutical Co Ltd
- Ticker
- 600285.SHG
- ISIN
- CNE000001501
- Exchange
- Shanghai Stock Exchange
- Listed since
- Sep 14, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,789
- Fiscal year end
- December
- Address
- No. 666, Jiangjun Road, Xinyang, China, 465550
- Phone
- 86 37 6298 8888
- Website
- lingrui.com
About Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Medical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, nutritional supplements, and anesthesiology. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules. The company also engages in industrial and real estate investment; technology research and development; ecological agriculture; and high-tech activities. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is headquartered in Xinyang, China.
Henan Lingrui Pharmaceutical Co Ltd management
8- Mr. Wei XiongChairman & GM · born 1985
- Mr. Peng YuChief Financial Officer · born 1969
- Mr. Xi Zhen WuDeputy GM & Director · born 1965
- Ms. Yan ChenDeputy GM & Director · born 1972
- Mr. Guo Xin FengSecretary of the Board & Director · born 1990
- Mr. Qiang YeDeputy General Manager · born 1972
- Mr. Lei LiDeputy General Manager · born 1983
- Xiuying HuAccounting Supervisor